Baidu
map

Immunity:细菌DNA环状双核苷酸同时诱导I型干扰素产生和激活转录因子NF-KB

2017-03-23 Leo.C MedSci原创

除了激活I型干扰素以外,环状双核苷酸还有激活转录因子NF-KB的重要功能。

细菌的DNA能够引起机体的免疫反应。免疫细胞,比如巨噬细胞通过表面的Toll-like receptor9,TLR9受体识别细胞外的细菌的DNA激活下游的免疫信号激活。细胞内的细菌的DNA则通过另外两种细胞内受体DDX41和STING识别。通常情况下,来自细菌的环状双核苷酸(cyclic dinucleotides)会被STING蛋白识别从而激活下游的免疫信号激活,主要是I型干扰素(TYPE I IFN)。所以STING蛋白被认为和细菌感染有密切关系。但是感染STING基因敲除的老鼠并没有展示出明显的细菌感染的不同。然而调节细菌所产生的环状双核苷酸的量,会是细菌感染的结果有明显不同。因此,从细菌的环状双核苷酸到STING蛋白之间可能存在这另外一种信号机制,从而影响细菌感染的结果。

在这一期的Immunity杂志里,Adelle McFarland及其同事发现除了STING蛋白以外,细菌的环状双核苷酸能过结合一种叫做RECON的蛋白。RECON蛋白是一种氧化还原酶,它的作用是结合并且抑制转录因子NF-KB的激活。转录因子NF-KB是机体调节免疫反应的重要因素。NF-KB的激活会转录一系列的抗感染的蛋白。环状双核苷酸结合RECON蛋白后,几乎彻底抑制它的还原酶的活性,从而失去抑制转录因子NF-KB的能力,导致下游免疫信号的放大。

这项研究发现了一个新的环状双核苷酸的结合蛋白。开辟了除了激活I型干扰素以外,环状双核苷酸还有激活转录因子NF-KB的重要功能。

原始出处:
Adelle P. McFarland, Shukun Luo, Fariha Ahmed-Qadri et al., Sensing of Bacterial Cyclic Dinucleotides by the Oxidoreductase RECON Promotes NF-κB Activation and Shapes a Proinflammatory Antibacterial State. Immunity, Volume 46, Issue 3, 21 March 2017, Pages 337-339. http://dx.doi.org/10.1016/j.immuni.2017.02.014

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-10-01 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-11-09 xsm918
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-03-25 jichang
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747228, encodeId=25ec1e472285f, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Oct 01 17:10:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030338, encodeId=1f33203033897, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Nov 28 16:10:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945606, encodeId=eaf6194560689, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Nov 09 19:10:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318224, encodeId=09231318224fe, content=<a href='/topic/show?id=685a101e4f8' target=_blank style='color:#2F92EE;'>#I型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10174, encryptionId=685a101e4f8, topicName=I型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536958, encodeId=d7261536958f4, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537461, encodeId=065f153e461c9, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Mar 25 09:10:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]

相关资讯

Science:非神经元细胞在疼痛发生和缓解方面的重要作用

在最新一期(11月3日)Science杂志的特刊:Pain中,纪如荣教授与复旦大学生科院张玉秋教授等人发表综述,概述了非神经元细胞,比如免疫细胞,神经胶质细胞,角质形成细胞,癌细胞,还有干细胞在疼痛发生和缓解方面的重要作用。

美国杜克大学医学中心的纪如荣教授是近年来国际慢性痛研究领域的重要领军人物之一,作为教育部***奖励计划讲座教授和复旦大学讲座教授,他的研究工作在国际上得到广泛认可,近年来,发表高质量的SCI学术论文一百余篇,发表的论文被引用次数超过15000次,有25篇以上论文单篇引用次数超过100次。

在最新一期(11月3日)Science杂志的特刊:Pain中,纪如荣教授与复旦大学生科院张玉秋教授等人发表综述,概述了非神经元细胞,比如免疫细胞,神经胶质细胞,角质形成细胞,癌细胞,还有干细胞在疼痛发生和缓解方面的重要作用。

疼痛问题不可小觑,这种不愉快的感觉和情绪方面的体验往往和实际或者潜在的伤害相联系,虽然从进化的角度

“超级细菌”现身美国,去年在中国首先发现! 可抵抗已知所有抗生素

据外媒报道,美国卫生官员26日报告称,美国发现首例对所有已知抗生素有抵抗力的细菌感染病例,如果这种超级细菌传播,可能造成日常感染的严重危险。 “我们有身处后抗生素世界的风险。”美国疾病控制和预防中心(CDC)主任弗里登(Tom Frieden)指的是宾夕法尼亚州一名49岁女性的尿路感染病例,这名女性在之前的五个月内没有外出旅行史。 弗里登在美国国家记者俱乐部午餐会上讲话时称,就连粘杆菌素(

Nature:突破性新方法合成出上百种新的大环内酯类抗生素

来自美国斯克里普斯研究所的Ming Yan和Phil Baran发表在同期Nature期刊上发表一篇新闻与评论类型的文章中,指出新的技术可能有助医学研究人员赶得上细菌进化的步伐。

Nature:揭示细胞焦亡作用机制,有望治疗细菌感染和败血症

抗生素耐药性的细菌感染越来越引发人们的担忧,就像败血症---免疫系统的最后一道防线不能够抵抗细菌感染,因而是非常致命的---那样。在一项新的研究中,来自美国波士顿儿童医院、哈佛医学院和布莱根妇女医院的研究人员描述了一种新方法潜在地控制败血症和引起败血症的失控的细菌感染。相关研究结果于2016年7月6日在线发表在Nature期刊上,论文标题为“Inflammasome-activated gasde

STM:用患者自体细菌开发护肤液,可杀死90%“嗜肉菌”

近日,科学家发明了一种方法,从遗传性过敏皮炎患者(atopic dermatitis patients)身上的微生物中提取抗菌液对抗金黄色酿脓葡萄球菌( Staphylococcus aureus)皮肤感染。

世卫组织:淋病或将无药可治

这是又一个由细菌感染的传染病即将面临无药可治窘境的信号。8月31日,世界卫生组织(WHO)发布了一份有关淋病治疗的新指导方针,反映了这种性传播疾病正在变得越来越难以治愈的发人深省的现状。WHO建议不再使用喹诺酮类药物,这是一种正变得越来越没用的抗生素。并且这也是第一次,该机构在提出应该怎么做的同时却没有给出可供选择的标准药物。据估计,由淋球菌引发的淋病每年在全球约导致7800万人感染。尽管有些人不

Baidu
map
Baidu
map
Baidu
map
Baidu
map